| |
original article |
Journal |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
Infusion & Chemotherapy |
2025―Mar―23 |
Endothelial protection in patients with coronary heart disease in combination with COVID-19: aspects of the different therapeutic strategies |
O.B. Dynnyk, S.Ye. Mostovyi, N.M. Bobok, V.Ye. Medvediev |
| 2 |
[GO] |
Infusion & Chemotherapy |
2025―Mar―23 |
Dynamics of the epidemiological indicators of tuberculosis in the Republic of Moldova during different periods and during the COVID-19 epidemics |
E.V. Lesnic, L.D. Todoriko |
| 3 |
[GO] |
Infusion & Chemotherapy |
2024―Dec―18 |
Clinical characteristics and risk factors for tuberculosis during the COVID-19 pandemic: a longitudinal analysis in a trans-border Ukrainian region |
E. Lesnic, L.D. Todoriko |
| 4 |
[GO] |
Infusion & Chemotherapy |
2024―Dec―18 |
Influence of heart rate variability on platelet hemostasis by average aggregate size in patients with chronic coronary heart disease in combination with COVID-19 |
V.Z. Netiazhenko, S.Ye. Mostovyi |
| 5 |
[GO] |
Infusion & Chemotherapy |
2024―Oct―09 |
Features of immune status in patients with pulmonary tuberculosis after the COVID-19 |
Yu.O. Matviienko, O.M. Rekalova, O.R. Panasiukova, V.M. Zhadan, S.H. Yasyr, A.V. Taranenko |
| 6 |
[GO] |
Infusion & Chemotherapy |
2024―Oct―09 |
Endothelial function in patients after severe or critical acute phase of COVID-19 one year after the disease onset |
T.O. Pertseva, N.O. Habshydze |
| 7 |
[GO] |
Infusion & Chemotherapy |
2024―Jun―25 |
The role of citicoline in the correction of cerebral blood flow disorders in patients with coronary artery disease in combination with COVID-19 |
V.Z. Netiazhenko, S.Ye. Mostovyi |
| 8 |
[GO] |
Infusion & Chemotherapy |
2024―Mar―27 |
Possibility of correction of cerebral blood flow disorders and central nervous system damage with citicoline in patients with coronary artery disease in combination with COVID-19 |
V.Z. Netiazhenko, S.Ye. Mostovyi |
| 9 |
[GO] |
Infusion & Chemotherapy |
2024―Mar―27 |
Radiological and morphological features of vanishing lung syndrome development in patients with COVID-19 community-acquired viral pneumonia |
O.K. Yakovenko, M.I. Lynnyk, I.V. Liskina, V.I. Ignatieva, G.L. Gumeniuk, M.G. Palivoda |
| 10 |
[GO] |
Infusion & Chemotherapy |
2024―Mar―27 |
Clinical, functional and imaging parallels in the objective status of patients after community-acquired COVID-19-associated pneumonia |
L.І. Konopkina, К.V. Rybalka |
| 11 |
[GO] |
Infusion & Chemotherapy |
2023―Dec―21 |
Pulmonary complications of COVID-19 in patients with diabetes |
A.V. Garnytska, O.S. Orlyk |
| 12 |
[GO] |
Infusion & Chemotherapy |
2023―Dec―21 |
Remote variants of the disappearing lung syndrome as a complication of COVID-19 pneumonia |
М.І. Lynnyk, М.І. Gumeniuk, O.K. Yakovenko, V.І. Іgnatieva, G.L. Gumeniuk, V.А. Svyatnenko |
| 13 |
[GO] |
Infusion & Chemotherapy |
2023―Dec―21 |
Diagnostic significance of KL-6 level in patients with community-acquired COVID-19-associated pneumonia in acute and post-acute periods of the pathological process |
L.І. Konopkina, К.V. Rybalka |
| 14 |
[GO] |
Infusion & Chemotherapy |
2023―Sep―29 |
Features of the course of pulmonary tuberculosis against the background of coronavirus infection according to computed tomography of the chest organs |
М.І. Lynnyk, V.І. Іgnatieva, G.L. Gumeniuk, V.А. Svyatnenko, V.Ye. Ivashchenko, О.P. Chobotar, М.G. Palivoda |
| 15 |
[GO] |
Infusion & Chemotherapy |
2023―Jun―16 |
The role of surfactant system dysfunction in the formation of dyspnea in patients with COVID-19-associated pneumonia |
L.I. Konopkina, O.O. Shchudro |
| 16 |
[GO] |
Infusion & Chemotherapy |
2023―Mar―29 |
Somatopsychic disorders in patients with community-acquired pneumonia associated with coronavirus disease (COVID-19) |
Т.О. Pertseva, L.I. Konopkina, Yu.V. Huba, О.О. Shchudro, N.О. Demian |
| 17 |
[GO] |
Infusion & Chemotherapy |
2023―Mar―29 |
Variants of the post-COVID syndrome course depending on age, gender, comorbidity and severity of COVID-19 |
L.D. Todoriko, O.S. Shevchenko |
| 18 |
[GO] |
Infusion & Chemotherapy |
2023―Mar―29 |
Surgical tactics for the treatment of subpleural and intra-pulmonary hematomas as a result of pneumonia caused by COVID-19 |
M.S. Opanasenko, S.M. Bilokon, B.M. Konik, O.V. Tereshkovych, S.M. Shalagay, L.I. Levanda, et al. (+5) M.I. Kalenychenko, V.B. Bychkovskyi, A.M. Stepaniuk, V.I. Lysenko, M.Yu. Shamray |
| 19 |
[GO] |
Infusion & Chemotherapy |
2023―Feb―16 |
Туберкульоз і COVID-19: що очікувати лікарям України? |
Л.В. Веселовський, С.В. Зайков |
| 20 |
[GO] |
Infusion & Chemotherapy |
2022―Oct―24 |
Differential diagnosis of the complicated course of COVID-19 pneumonias and infectious lung destruction |
O.K. Yakovenko, M.I. Lynnyk, I.V. Liskina, V.I. Ignatieva, G.L. Gumeniuk, V.V. Sokolov |
| 21 |
[GO] |
Infusion & Chemotherapy |
2022―Oct―24 |
Antiviral activity of aminocaproic acid against SARS-CoV-2: review of the literature and results of the first experimental study |
J. Chiaravalli, A. Verneuil, V. Osiichuk, D. Golyshkin, O.Ya. Dziublyk, M.I. Gumeniuk, O.S. Denysov |
| 22 |
[GO] |
Infusion & Chemotherapy |
2022―May―25 |
Pathogenetic treatment of patients with COVID-19 at the outpatient stage |
M.M. Ostrovskyi, L.I. Konopkina, K.Yu. Gashynova, G.L. Gumeniuk, D.V. Dobrianskyi, O.L. Bororova |
| 23 |
[GO] |
Infusion & Chemotherapy |
2022―May―25 |
Clinical case of concomitant tuberculosis and COVID-19 on the background of Churg-Strauss syndrome |
О.М. Raznatovska, Yu.V. Myronchuk, O.S. Shalmin, A.V. Fedorec |
| 24 |
[GO] |
Infusion & Chemotherapy |
2022―May―25 |
Determination of dynamics and stage of development of COVID-19 pneumonia based on digital software processing of images of computed tomography of the chest |
O.K. Yakovenko, Ya.O. Dziublyk, M.I. Lynnyk |
| 25 |
[GO] |
Infusion & Chemotherapy |
2022―May―25 |
Lung lever after COVID-19: clinical-X-ray, surgical and morphological characteristics |
Yu.I. Feshchenko, М.S. Opanasenko, I.V. Liskina, S.M. Bilokon, O.V. Tereshkovych, B.М. Konik, et al. (+6) L.I. Levanda, L.M. Zagaba, M.Yu. Shamray, M.I. Kalenychenko, V.I. Lysenko, S.М. Shalagay |
| 26 |
[GO] |
Infusion & Chemotherapy |
2022―May―25 |
Endothelium is the main target of coronavirus infection |
M.V. Bondar, M.M. Pylypenko, O.A. Loskutov |
| 27 |
[GO] |
Infusion & Chemotherapy |
2021―Dec―27 |
Risks of using pre-event time scale and ordinal scale measurements in COVID-19 clinical trials |
M.V. Yashchenko |
| 28 |
[GO] |
Infusion & Chemotherapy |
2021―Dec―27 |
Diagnostics of lesions of parenchymatic organs in COVID-19 with the application of digital software processing of computer tomography images |
М.І. Lynnyk, І.V. Liskina, М.І. Gumeniuk, V.І. Іgnatieva, G.L. Gumeniuk, V.А. Svyatnenko, et al. (+2) І.О. Panashchuk, V.Y. Ivashchenko |
| 29 |
[GO] |
Infusion & Chemotherapy |
2021―Dec―27 |
Inhaled antiseptics and inhaled antiviral non-prescription drugs in the prevention of ARVI, in particular COVID-19: an epidemiological study |
Yu.I. Feshchenko, M.I. Gumeniuk, М.І. Lynnyk, O.Ya. Dziublyk, M.M. Kuzhko, О.V. Tereshkovych, et al. (+5) O.V. Khmel, I.O. Panashchuk, M.V. Yashchenko, О.S. Denysov, Т.А. Sprynsian |
| 30 |
[GO] |
Infusion & Chemotherapy |
2021―Sep―30 |
Diagnosis of disappearing lung syndrome as a complication of non-hospital pneumonia of viral etiology (COVID-19) |
Y.I. Feshchenko, М.І. Lynnyk, М.І. Gumeniuk, I.A. Kalabukha, V.І. Іgnatieva, G.L. Gumeniuk, et al. (+3) O.R. Tarasenko, V.E. Ivaschenko, M.G. Palivoda |
| 31 |
[GO] |
Infusion & Chemotherapy |
2021―Sep―30 |
The impact of the COVID-19 pandemic on the financial sector in medicine: features of centralized state procurement of drugs and medical devices in Ukraine for the period 2018-2021 |
O.S. Denysov |
| 32 |
[GO] |
Infusion & Chemotherapy |
2021―Jul―11 |
Pathogenetic syndrome management of a patient with COVID-19 |
E.M. Khodosh |
| 33 |
[GO] |
Infusion & Chemotherapy |
2021―Jul―11 |
Neuroinvasion and neurological complications in COVID-19 |
O.A. Loskutov |
| 34 |
[GO] |
Infusion & Chemotherapy |
2021―Jul―11 |
Organoprotection in patients with COVID-19 |
V.K. Tashchuk |
| 35 |
[GO] |
Infusion & Chemotherapy |
2021―Jul―11 |
Features of infusion therapy in patients of the therapeutic profile during the COVID-19 pandemic |
O.A. Halushko |
| 36 |
[GO] |
Infusion & Chemotherapy |
2021―Jul―11 |
Tuberculosis in the context of the COVID-19 pandemic: what to expect and how to act? |
L.D. Todorico |
| 37 |
[GO] |
Infusion & Chemotherapy |
2021―Jul―11 |
2020 challenge: the potential options of COVID-19 therapy |
S.V. Kovalenko |
| 38 |
[GO] |
Infusion & Chemotherapy |
2021―Jul―11 |
The experience of management of COVID-19: focus on the pneumonia |
L.V. Moroz |
| 39 |
[GO] |
Infusion & Chemotherapy |
2021―Jul―11 |
Peculiarities of antimicrobial therapy of viral and bacterial pneumonia in patients with coronavirus disease |
O.M. Nesterenko |
| 40 |
[GO] |
Infusion & Chemotherapy |
2021―Jul―11 |
Peculiarities of care for patients with coronavirus infection. Important safety issues for health care workers |
A.M. Savych |
| 41 |
[GO] |
Infusion & Chemotherapy |
2021―Jul―10 |
Standardized protocol for ultrasound diagnosis of the lungs with COVID-19 |
O.M. Safonova, O.B. Dynnyk, G.L. Gumeniuk, V.A. Lukiianchuk, H.V. Linska, M.S. Brovchenko, et al. (+2) V.V. Panasiuk, S.O. Soliaryk |
| 42 |
[GO] |
Infusion & Chemotherapy |
2021―Jul―10 |
Diagnostics of complicated course of community-acquired pneumonia of viral etiology (COVID-19) via using chest computed tomography |
М.І. Lynnyk, V.І. Іgnatieva, G.L. Gumeniuk, V.А. Svyatnenko, O.R. Tarasenko, O.L. Bororova |
| 43 |
[GO] |
Infusion & Chemotherapy |
2021―Jul―10 |
Evaluation of the treatment efficacy in the patients with viral etiology community acquired pneumonia (COVID-19) with the use of syndrome-pathogenetic small volume infusion therapy according to computer tomography data |
М.І. Lynnyk, V.І. Іgnatieva, G.L. Gumeniuk, O.R. Tarasenko, S.H. Opimakh, I.V. Chumak, et al. (+3) L.A. Halai, V.V. Polischuk, N.А. Vlasova |
| 44 |
[GO] |
Infusion & Chemotherapy |
2021―Jul―09 |
Therapy of patients with COVID-19: clinical studies and recommendations in different countries |
S. V. Zaikov |
| 45 |
[GO] |
Infusion & Chemotherapy |
2020―Oct―12 |
Combination of the therapy of the anticoagulants and Tivortin in patients with cardiac ishemia at COVID-19 |
M.J. Dzhumaeva, A.I. Tabarov, Kh.T. Fayzulloev |
| 46 |
[GO] |
Infusion & Chemotherapy |
2020―Oct―12 |
Prospects of infusion therapy in the treatment of severe pulmonary tuberculosis in combination with COVID-19 |
L.D. Todoriko, M.I. Gumeniuk, I.O. Semianiv, T.A. Sprynsian, O.S. Denysov |
| 47 |
[GO] |
Infusion & Chemotherapy |
2020―Oct―12 |
Peculiarities of pulmonary tuberculosis in a COVID-19 pandemic |
L.D. Todoriko, І.О. Сем’янів |
| 48 |
[GO] |
Infusion & Chemotherapy |
2020―Oct―12 |
Features of infusion therapy in therapeutic patients during the COVID-19 pandemic |
O.A. Halushko |
| 49 |
[GO] |
Infusion & Chemotherapy |
2020―Oct―12 |
Role of markers of inflammation, severity and infusion therapy in COVID-19-defined pneumonia |
E.M. Khodosh |
| 50 |
[GO] |
Infusion & Chemotherapy |
2020―Oct―12 |
Peculiarities of antimicrobial therapy of viral-bacterial pneumonia in patients with coronavirus disease |
O.M. Nesterenko |
| 51 |
[GO] |
Infusion & Chemotherapy |
2020―Oct―10 |
COVID-19 and comorbid chronic diseases |
S. V. Zaikov |
| 52 |
[GO] |
Infusion & Chemotherapy |
2020―Oct―10 |
Peculiarities of tuberculosis in the COVID-19 pandemic |
L. D. Todoriko, I. O. Semianiv |
| 53 |
[GO] |
Infusion & Chemotherapy |
2020―Sep―11 |
Methods of visualization in the diagnosis of COVID-19 community-acquired pneumonia |
М.І. Gumeniuk, V.І. Іgnatieva, М.І. Lynnyk, G.L. Gumeniuk, V.А. Svyatnenko, M.G. Palivoda |
| 54 |
[GO] |
Infusion & Chemotherapy |
2020―Sep―11 |
Viral load as a marker of the risk of severe course and progression of COVID-19: a review |
Y. I. Feshchenko |
